EPIs and Immunotherapy – An answer to drug-resistant tuberculosis

Cite this:
[1]
A. . Roy, A. . Hussain, K. . Sinha, M. . Praharaju*, and S. . Khatun, “EPIs and Immunotherapy – An answer to drug-resistant tuberculosis”, ijmhs, vol. 10, no. 10, pp. 1306–1319, Oct. 2020.
© 2022 Interactive Protocols
RIGHTS & PERMISSIONS
Article Views
270
Altmetric
1
Citations
-
LEARN ABOUT THESE METRICS
   PDF  

Abstract

Tuberculosis (TB), primarily caused by Mycobacterium tuberculosis (Mtb) remains one of the fatal contagious diseases accountable for millions of deaths yearly across the globe – droplet or aerosol being the mode of transmission. Apart from the peculiar microbial physiology and drug efflux pumps with drug modifying enzymes that make Mtb impervious to the existing drug regimen recommended by the WHO via DOTS, lack of social awareness and misuse or mismanagement of drugs make it even more deadlier transforming Mtb to MDR-TB & XDR-TB, thus increasing the number of TB cases globally per annum. Amidst the dire need to combat the rising cases of drug-resistant TB, this article discusses the potential use of phytochemical derived efflux pump inhibitors (EPIs) and immunotherapy to fight TB with a brief insight into the molecular mechanism and structure of drug-efflux pumps found in Mtb.

Keywords: Mycobacterium tuberculosis, efflux pumps, DOTS, efflux pump inhibitors (EPIs), immunotherapy.

KEYWORDS:

 Special Issue

Article Metrics Graph

Chart Graph | Range Graph

Content

Section

Source

License

All paper submissions must carry the following duly signed by all the authors:
“I certify that I have participated sufficiently in the conception and design of this work and the analysis of the data (wherever applicable), as well as the writing of the manuscript, to take public responsibility for it. I believe the manuscript represents valid work. I have reviewed the final version of the manuscript and approve it for publication. Neither has the manuscript nor one with substantially similar content under my authorship been published nor is being considered for publication elsewhere, except as described in an attachment. Furthermore I attest that I shall produce the data upon which the manuscript is based for examination by the editors or their assignees, if requested.”